Abstract
The Heart Outcomes Prevention Evaluation (HOPE) study demonstrated that the angiotensin‐converting enzyme inhibitor, ramipril, significantly reduces mortality, myocardial infarction and stroke in high‐risk cardiovascular patients, beyond the benefits from blood pressure lowering. The tolerability of ramipril 10 mg/day has been an important concern when applying these results. Following the same criteria as the HOPE study, we investigated the adverse effects profile and tolerability of 10 mg ramipril in high‐risk patients at our institution. In total, 92 patients with high cardiovascular risk were eligible for this study. Initially, ramipril was prescribed 2.5 mg orally once daily, and then titrated up to 5.0, 7.5, and 10.0 mg/day at 1‐month intervals. The target maintenance dose was 10 mg/day. All adverse events were recorded during at least 3 months of follow‐up. After 4‐6 months of the titration protocol, only 18 patients (25.3%) reached and remained on ramipril 10 mg/day; 11 (15.5%), 22 (30.9%), and 20 patients (28.2%) remained on 2.5, 5.0, and 7.5 mg/day, respectively. Twenty‐one patients (22.6%) had at least one adverse event. Twelve patients (13.0%) stopped treatment because of adverse effects. A total of 23 episodes of adverse events were reported, including cough (15.1%), dizziness (6.0%), and hypotension (2.4%). Ramipril was relatively well tolerated in our study population. However, only one‐quarter of our patients reached the target maintenance dose of 10 mg/day. Dry cough, dizziness, and hypotension were the major side effects. About 15% of our patients discontinued ramipril treatment, which is comparable with previous reports.
Keywords: ACE inhibitor, adverse effect, tolerability
Full Text
The Full Text of this article is available as a PDF (257.0 KB).
References
- 1. Vuong AD, Annis LG. Ramipril for the prevention and treatment of cardiovascular disease. Ann Pharmacother. 2003; 37: 412–419. [DOI] [PubMed] [Google Scholar]
- 2. Warner GT, Perry CM. Ramipril: a review of its use in the prevention of cardiovascular outcomes. Drugs. 2002; 62: 1381–1405. [DOI] [PubMed] [Google Scholar]
- 3. Kleinert S. HOPE for cardiovascular disease prevention with ACE‐inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet. 1999; 354: 841. [DOI] [PubMed] [Google Scholar]
- 4. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003; 107: 1284–1290. [DOI] [PubMed] [Google Scholar]
- 5. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO‐HOPE. Diabetes Metab Res Rev. 2002; 18: S82–S85. [DOI] [PubMed] [Google Scholar]
- 6. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin‐converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329: 1456–1462. [DOI] [PubMed] [Google Scholar]
- 7. Carroll CA, Coen MM, Rymer MM. Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high‐risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study. Clin Ther. 2003; 25: 1248–1261. [DOI] [PubMed] [Google Scholar]
- 8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342: 145–153. [DOI] [PubMed] [Google Scholar]
- 9. Schieffer B, Schieffer E, Hilfiker‐Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000; 101: 1372–1378. [DOI] [PubMed] [Google Scholar]
- 10. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin‐converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994; 90: 2056–2069. [DOI] [PubMed] [Google Scholar]
- 11. Singh NP, Uppal M, Anuradha S, et al. Angiotensin converting enzyme inhibitors and cough — a north Indian study. J Assoc Physicians India. 1998; 46: 448–451. [PubMed] [Google Scholar]
- 12. Wu N, Zhu JR, Chen KA. Tolerability of ramipril 10 mg/day in high‐risk cardiovascular Chinese patients. Clin Drug Invest. 2002; 22: 771–781. [Google Scholar]
- 13. Carre A, Vasmant D, Elmalem J, et al. Tolerability of ramipril in a multicenter study of mild‐to‐moderate hypertension in general practice. J Cardiovasc Pharmacol. 1991; 18: S141–S143. [PubMed] [Google Scholar]
- 14. Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin‐angiotensin system and bradykinin B2 receptor with ACE‐inhibitor‐related cough. J Hum Hypertens. 2002; 16: 857–863. [DOI] [PubMed] [Google Scholar]
- 15. Lee YJ, Tsai JC. Angiotensin‐converting enzyme gene insertion/deletion, not bradykinin B2 receptor ‐58T/C gene polymorphism, associated with angiotensin‐converting enzyme inhibitor‐related cough in Chinese female patients with non‐insulin‐dependent diabetes mellitus. Metabolism. 2001; 50: 1346–1350. [DOI] [PubMed] [Google Scholar]
- 16. Furuya K, Yamaguchi E, Hirabayashi T, et al. Angiotensin‐I‐converting enzyme gene polymorphism and susceptibility to cough. Lancet. 1994; 343: 354. [DOI] [PubMed] [Google Scholar]
- 17. Ding PY, Hu OY, Pool PE, et al. Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin‐converting enzyme inhibitors?. J Hum Hypertens. 2000; 14: 163–170. [DOI] [PubMed] [Google Scholar]